About
Drug Treatment to Inhibit Dementia
MemoBoost is developing a pioneering drug treatment designed to inhibit the onset of dementia. The companys technology is based on research into the scientific foundations of learning and memory in the brain. MemoBoost is headed by Prof. Edi Barkai of the University of Haifas Sagol Department of Neurobiology and the head of the Laboratory for Neurobiology of Learning and Memory. Prof. Barkai is on the path to developing a cognitive/learning-enhancing drug that may counter the cognitive deficits suffered by dementia patients. Prof. Barkais research has identified a specific receptor in the brain, in the mGluR family, which inhibits learning when its excitability is blocked and improves learning when its excitability is consistently enhanced. Using a research compound that activates this receptor, Prof. Barkais group has successfully shown that learning is significantly enhanced in a validated animal model of learning. The compound is currently being modified and tested in order to develop a drug that will serve as a potent cognitive enhancer to tackle the onset of dementia and other cognitive deficits.
Identity
| Name | MemoBoost |
|---|---|
| Slug | memoboost |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoKmNodMIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, May 2024 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Haifa |
| HQ address | Abba Khoushy Ave 199, Haifa, Israel |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}